Despite reporting that sales continued to decline in the first quarter, Valeant Pharmaceuticals’ (NYSE:VRX) share price is up 47% since the end of April.
What gives? Personally, I think shares are rallying because short-sellers are rushing to cover after realizing it’s less likely that the company will default on its debt soon.